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Abstract
Background: Bloodstream infections remain one of the major challenges in intensive care units, leading to sepsis
or even septic shock in many cases. Due to the lack of timely diagnostic approaches with sufficient sensitivity,
mortality rates of sepsis are still unacceptably high. However a prompt diagnosis of the causative microorganism is
critical to significantly improve outcome of bloodstream infections. Although various targeted molecular tests for
blood samples are available, time-consuming blood culture-based approaches still represent the standard of care
for the identification of bacteria.
Methods: Here we describe the establishment of a complete diagnostic workflow for the identification of
infectious microorganisms from seven septic patients based on unbiased sequence analyses of free circulating DNA
from plasma by next-generation sequencing.
Results: We found significant levels of DNA fragments derived from pathogenic bacteria in samples from septic
patients. Quantitative evaluation of normalized read counts and introduction of a sepsis indicating quantifier (SIQ)
score allowed for an unambiguous identification of Gram-positive as well as Gram-negative bacteria that exactly
matched with blood cultures from corresponding patient samples. In addition, we also identified species from
samples where blood cultures were negative. Reads of non-human origin also comprised fragments derived from
antimicrobial resistance genes, showing that, in principle, prediction of specific types of resistance might be
possible.
Conclusions: The complete workflow from sample preparation to species identification report could be
accomplished in roughly 30 h, thus making this approach a promising diagnostic platform for critically ill patients
suffering from bloodstream infections.
Keywords: Sepsis, Diagnostics, Next-generation sequencing, Circulating nucleic acids
Background
Sepsis remains a challenge in intensive care medicine, its
incidence increasing continuously over the past decades
[1, 2]. Despite massive efforts in sepsis research, new
therapeutic approaches are rare and mortality in patients
with septic shock still remains unacceptably high [1, 2].
In addition to an early focus on control, recent guide-
lines recommend the initiation of an empiric antibiotic
therapy as early as possible (preferably within 1 h) follow-
ing diagnosis of sepsis [3]. However, the identification of
the causative pathogen as well as its resistance pattern is
crucial for early optimization of the antimicrobial treat-
ment regime. In this context, culture-based diagnostic
procedures (e.g., blood cultures) represent the standard of
care, although they are associated with relevant limitations
[3, 4]: (i) depending on microbiological growth, it often
takes up to 5 days for results to become available; and (ii)
culture-based diagnostic procedures often reveal false
negative results due to the administration of an empiric
antibiotic therapy. Accordingly, patients suffering from
septic disease are at high risk for antimicrobial overtreat-
ment, antibiotics-related toxicity, and the selection of
multi-drug resistant pathogens due to the inadequate and
prolonged use of broad spectrum antibiotics. In this
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context, culture-independent molecular diagnostic proce-
dures (e.g., PCR-based techniques) have already been in-
troduced for the identification of the causative pathogen
in infected patients [5–9]. However, the occurrence of am-
biguous results as well as limitations in the quantitative
measurement of the bacterial load in patients’ samples and
detection of antibiotic resistance markers are known limi-
tations of these PCR-based diagnostic approaches. There-
fore, the concept of our work was to develop an
alternative diagnostic platform for the identification of in-
fectious microorganisms based on unbiased sequence ana-
lyses of circulating cell-free DNA (cfDNA) from plasma
samples of septic patients by next-generation sequencing
(NGS). In addition, we demonstrate the applicability of
NGS for the detection of antibiotic resistance markers in
plasma.
Methods
Study design
Human data are from a secondary analysis of a sub-
set of patients participating in the RAMMSES trial
(German Clinical Trials Register, DRKS00000505)
[10]. An amendment to the existing approval (Trial-
Code-Nr. S123-2009) was written and approved by the
local ethics committee.
The observational clinical study was conducted in the
surgical intensive care unit (ICU) of Heidelberg Univer-
sity Hospital, Germany. Study and control patients or
their legal designees signed a written informed consent.
In total, 120 patients in three groups were consecutively
enrolled into the study from August 2009 to July 2010.
The three groups included: (1) 60 patients with septic
shock according to the criteria of the International
Sepsis Definitions Conference [11] and due to docu-
mented or suspected infection according to the criteria of
the International Sepsis Forum Consensus Conference on
Definitions of Infection in the Intensive Care Unit [12]; (2)
30 postoperative controls following major abdominal sur-
gery without any evidence of infection; and (3) 30 healthy
volunteers. Plasma samples from patients with septic
shock were collected at sepsis onset (T0) and 24 h (T1),
4 days (T2), 7 days (T3), 14 days (T4), and 28 days (T5)
later. Plasma samples from the postoperative group were
collected prior to surgery (T0), immediately following the
end of the surgical procedure (T1), and 24 h later (T2).
Plasma samples from the volunteer group were collected
once (T0).
For this secondary analysis, patients’ electronic
medical records were retrospectively screened for re-
sults from blood culture testing during septicemia
and patients were selected according to availability of
microbiological data for similar time points, which
led to the smaller sample size within this proof-of-
concept study.
Clinical microbiology
Blood culture testing in Heidelberg University Hospital
is routinely performed as described [13]. Whole blood
samples are obtained via direct venipuncture (e.g., ante-
cubital vein) applying sterile techniques and 10 mL
blood is inoculated to both an aerobic and an anaerobic
liquid culture medium (BACTEC PLUS, BD Biosciences,
Heidelberg, Germany). Cultures are incubated for 5 days
(BACTEC, BD Biosciences, Heidelberg, Germany) and
positive cultures are analyzed according to approved in-
house hospital standard techniques, including identifica-
tion by VITEK2 (Biomerieux, Nuertingen, Germany) or
MALDI TOF (Bruker, Madison, WI, USA) and automated
antimicrobial susceptibility testing (VITEK 2). Quantifica-
tion of HSV1 DNA and cytomegalovirus DNA from
plasma or tracheal secretion was performed via quantita-
tive real time PCR as previously described [14]. Cultiva-
tion of wound swabs and catheter and stool samples was
carried out as previously described [15, 16].
Plasma preparation and nucleic acid isolation
Plasma was prepared from blood samples by centrifuga-
tion for 10 min at 292 × g and 4 °C, snap frozen, and
stored at −80 °C until further processing. Nucleic acids
were isolated from thawed plasma after a centrifugation
step of 5 min at 1000 × g with the Circulating Nucleic
Acid Kit (Qiagen) according to the manufacturer’s
protocol with the following exceptions: plasma volumes
after centrifugation (from 130 to 790 μl) were adjusted
to 1 ml with sterile phosphate buffered saline. Final elu-
tion of the nucleic acids from the spin column was carried
out with 30 μl molecular biology grade water (5 Prime,
Germany). Contamination controls were prepared follow-
ing the same procedure, starting from 1 ml molecular
biology grade water (5 Prime, Germany) and 1 ml of ster-
ile phosphate buffered saline, which was prepared using
the Circulating Nucleic Acid Kit (Qiagen). The cfDNA
was quantified with the Qubit dsDNA HS Assay Kit (Life
Technologies) and quality was assessed by the High Sensi-
tivity DNA Kit on a Bioanalyzer (Agilent).
Preparation of NGS libraries and sequencing
Libraries for NGS were prepared from 1 ng cfDNA using
the Nextera XT library preparation Kit (Illumina) ac-
cording to the manufacturer’s protocol, with the excep-
tion that the final elution after bead clean-up was
carried out in 34 μl of resuspension buffer (Illumina). A
further contamination control was added by using 5 μl
of molecular biology grade water (5 Prime, Germany) as
template for the Nextera XT Library Preparation Kit
(Illumina). Sequencing of the libraries was performed on
a HiSeq2500 (Illumina), resulting in 25–30 million 100-bp
single end reads, on average, per sample. Since samples V6,
V22, and P6 were initially sequenced with considerably
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higher numbers of reads, those samples were randomly re-
duced in silico to 30 million representative subsampled
reads.
Bioinformatics
Raw reads were cleared from potential adapter contam-
ination, quality controlled, and, if necessary, trimmed
using BBDuk (https://sourceforge.net/projects/bbmap/).
To pass the quality filter, read quality needed to surpass
a Phred score of 20 and achieve a minimal length of
50 bp after trimming of low quality and adapter bases.
Subsequently, NextGenMap was used to align quality-
controlled reads to the human reference genome (hg19)
requiring a minimum identity between read and refer-
ence genome of 80 %. Reads mapping to the human
reference genome and reads with low complexity (con-
secutive stretches of di- and trinucleotides along the
whole read sequence) were excluded from further ana-
lysis [17]. Finally, Kraken was used to assign reads to
systematic classification using the RefSeq database (re-
lease version 68) comprising 35,749 bacterial and 4340
viral genomes complemented by 12 selected fungal
genomes (Additional file 1: Table S1). Since several
Xanthomonas species are described as well-known con-
taminants, we excluded Xanthomonas reads as well as
the Illumina sequencing spike-in PhiX [18].
To quantitatively compare the number of reads that
map to different microbial taxonomic classifications be-
tween different samples, we normalized the read counts
by the respective library size (Table 1).
We introduced the n × (s + 1) dimensional count
matrix D, where n is the number of control samples and
s the number of species detected in all samples. Thus,
Dij defines the number of reads found in control sample
i for species j. Di,(s + 1) defines the number of reads
which cannot be assigned to any species. One notes that
Di,(s + 1) is usually larger than the Dijs. Then Eq. 1 is the
maximum likelihood estimate of the probability to ob-
serve species j in a control sample:
p^j ¼
Xn
k¼1Dk; jXn
k¼1Dk;sþ1
; j ¼ 1; …; sþ 1 ð1Þ
Since the number of reads for one species is typically
low, we assumed that the read counts for species j are
Poisson distributed with parameter:
λj ¼
Xn
k¼1Dk; j
n
: ð2Þ
To test this assumption for each species a standard χ2
goodness of fit test is performed.
For reads sequenced from patient plasma, the same
data processing pipeline is applied, which yields a read
count vector C = (C1, …, Cs, Cs + 1). Based on the Poisson
distribution with species-specific parameter λj, the p value
to observe at least Cj read counts in a patient sample is
computed as:
P X≥Cjj λj
  ¼
X
k≥Cj
e−λjλkj
k!
: ð3Þ
If this p value is small, then one would reject the hy-
pothesis that the read count of species j in the patient
sample follows the Poisson distribution derived from the
healthy individuals and conclude that the respective spe-
cies occurs too often in the patient.
Now, with the given species specific λ we can compute
the sepsis indicating quantifier (SIQ) score as follows:
SIQj ¼ Cj  −

log10

PðX≥CjjλjÞ

ð4Þ
The SIQ score now gives rise to a quantitative and
probabilistic assessment of every detected microbe in
the respective sample.
In order to identify resistance genes, potential micro-
bial reads were mapped against the downloaded CARD
resistance gene database using NextGenMap with the
following parameters: sensitivity (-s) and minimal num-
ber of mapped residues (-R) of 0.9. We required 100 %
identity between read sequence and target sequence in
the CARD database.
Results
Elevated levels of cfDNA in septic patients reveal
microbial DNA fragments
In order to test the diagnostic potential of cfDNA to
identify infecting microorganisms in septic patients, in
total 62 plasma samples from septic patients (S, n = 7),
healthy volunteers (V, n = 12), and patients that under-
went abdominal surgery (P, n = 6) at different time
points were analyzed in this study. Mean ages were
70.5 years, 26.4 years, and 64.2 years for groups S, V,
and P, respectively (Table 1). Septic patients were moni-
tored by a comprehensive clinical microbiology diag-
nostic workup. cfDNA isolation from patient and
control plasma revealed a characteristic, predominantly
apoptosis-associated size pattern [19, 20] (Additional file
2: Figure S1). Due to the small cohort size, it was not
possible to draw statistically relevant conclusions; how-
ever, concentrations of cfDNA tend to be increased in
patients with septic shock (S, mean 197.23 ng/ml), espe-
cially at the onset of sepsis (S T0, mean 377.30 ng/ml)
(Fig. 1), which is consistent with other reports [21, 22].
Elevated concentrations were also measured in plasma
of post-surgery patients (P T1–T2, mean 451.63 ng/ml)
compared with uninfected controls before surgery and
healthy volunteers (P T0, mean 149.33 ng/ml; V, mean
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55.43 ng/ml). cfDNA sequencing revealed a similar pro-
portion of human reads for all groups with 96.36,
96.52, and 96.21 % in groups S T0, V, and P T0, re-
spectively (Table 1). The average classified reads were
higher in septic patients at the onset of sepsis com-
pared with the control groups (9.82, 3.50, and 2.64 %
in groups S T0, V, and P T0), indicating a higher bac-
terial load. It should be noted, however, that the pro-
portion of classified reads includes bleed-through
PhiX reads and reads classified as from Xanthomonas
campestris, which were discarded as contaminants in
downstream analysis.
Establishment of the SIQ score as a quantitative score for
pathogen calling
Figure 2a summarizes the principle for diagnostic assess-
ment of microbial reads for a patient in comparison with
uninfected controls. Normalized read counts of classi-
fied, non-human reads for each plasma sample were
calculated, resulting in a quantification of distinct spe-
cies (Additional file 3: Table S6). In case of patient S9
with positive blood cultures for Enterobacter cloacae at
the onset of sepsis, distinctly higher numbers of E. clo-
acae reads were found compared with a set of species
with normalized reads at very low abundances (Fig. 2b).
Table 1 Patient characteristics, cfDNA concentration, and sequencing statistics
ID Time Sex Age (years) cfDNA (ng/ml plasma) Sequencing depth Human reads (%) Unmapped (%) Classified (%)
S9 T0 M 82 120.59 30,650,143 92.90 7.10 28.90
S10 T0 M 68 307.83 27,199,593 98.70 1.30 2.85
S11 T0 M 62 805.50 27,073,879 93.61 6.39 20.73
S19 T0 F 62 101.30 26,892,684 98.45 1.55 4.75
S23 T0 M 79 146.70 24,917,032 97.12 2.88 3.85
S26 T0 M 66 1088.90 32,529,889 96.60 3.40 3.24
S60 T0 F 70 70.29 27,381,853 97.10 2.90 4.40
Average S T0 70 377.30 28,092,153 96.36 3.64 9.82
Average S all 70 197.23 25,960,730 97.79 2.21 4.24
V5 M 24 35.80 34,203,815 81.90 18.10 12.38
V6 M 29 27.40 30,000,000 98.96 1.04 2.25
V7 F 22 76.40 21,004,601 96.58 3.42 2.35
V13 F 26 23.50 24,449,232 98.09 1.91 3.26
V14 M 28 38.60 37,971,559 97.42 2.58 1.79
V15 M 27 166.80 24,505,696 97.60 2.40 2.88
V16 F 29 70.60 27,220,925 97.06 2.94 2.67
V17 M 26 28.40 20,225,374 98.61 1.39 3.30
V18 M 28 48.80 19,157,938 98.14 1.86 2.46
V19 F 31 33.40 25,776,920 97.08 2.92 2.87
V21 M 22 67.30 25,220,391 97.72 2.28 2.51
V22 M 25 48.20 30,000,000 99.15 0.85 3.25
Average V 26 55.43 26,644,704 96.52 3.48 3.50
P1 T0 M 58 50.20 22,389,868 96.95 3.05 1.79
P2 T0 M 53 552.00 30,000,000 98.57 1.43 3.35
P3 T0 F 62 109.50 18,796,573 94.69 5.31 1.38
P4 T0 F 72 36.42 28,457,744 94.91 5.09 4.59
P5 T0 M 64 65.38 28,547,804 95.48 4.52 3.72
P7 T0 M 76 82.50 28,845,398 96.69 3.31 1.00
Average P T0 64 149.33 26,172,898 96.21 3.79 2.64
Average P T1–T2 64 451.63 25,406,269 97.72 2.28 2.14
Average P all 64 350.86 25,661,812 97.22 2.78 2.31
Patients were grouped as septic patients (S), healthy volunteers (V), and non-infected patients following major abdominal surgery (P). Of the total reads (sequencing
depth), all reads mapped to human reference genome hg19 are classified as human reads; the remaining reads are denoted as unmapped. The proportion of
unmapped reads classified to any species using Kraken are specified here as classified. F female, M male
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Fig. 1 Distribution of cfDNA concentrations over different patient groups and time points. a Comparison of cfDNA concentrations between
healthy volunteers (V), septic patients at the onset of sepsis (S T0), and non-infected patients following major abdominal surgery (P). b Alterations
in cfDNA concentrations of septic patients’ plasma samples collected over the observational period of the trial. Samples were obtained at sepsis
onset (T0), after 24 h (T1), 4 days (T2), 7 days (T3), 14 days (T4), and 28 days (T5). c Comparison of cfDNA concentrations in patients undergoing
major abdominal surgery without evidence of infection. Blood samples from the postoperative group were collected prior to surgery (T0), immediately
following the end of the surgical procedure (T1), and 24 h later (T2)
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To evaluate the significance of read abundances for all
species classified, normalized read counts were com-
pared for each species between all septic patients and
controls. The abundance of normalized reads for E.
cloacae in patients and controls was close to zero except
for time point T0 of patient S9 (1,907.33; Fig. 2c;
Additional file 4: Figure S2). In contrast, normalized
read counts for a common skin commensal like
Propionibacterium acnes varied significantly between all
samples and higher abundances were especially detected
in samples obtained from uninfected controls (Fig. 2d;
Additional file 5: Figure S3). This effect was observed for
several bona fide contaminant species (Additional file 6:
Table S2). To support discrimination by relevance, we
combined abundance and unlikeliness of observed read
counts for each species found in a sample. The log2 ra-
tio of normalized reads is plotted versus 1 − p value
(Fig. 2e). Species which are significantly represented in a
sample with a p value <0.05 compared with controls are
considered significant (Fig. 2e). An individual SIQ
score was calculated as a product of abundance and
significance and is indicated by the radius of the
corresponding data point. Therefore, the species with
highest relevance found in cfDNA of patient S9 at
the onset of sepsis was E. cloacae with a SIQ score of
586,795 (Additional file 7: Table S3). In contrast, no
significant SIQ scores were observed for uninfected
postoperative patients (Additional file 7: Table S3 and
Additional file 8: Figure S4)
Clinical relevance of the SIQ score
The SIQ score can also be used for time-course moni-
toring of a patient’s progression and response to targeted
treatment. We therefore compared the SIQ score with
clinical microbiology data, supplemented with data on
anti-infective therapy (Additional file 9: Table S5) over a
trial period of 28 days. Patient S10 developed septic
shock due to severe pneumonia following a gastrectomy
Fig. 2 Rationale of the SIQ score and SIQ plot. a Outline for obtaining a SIQ score and SIQ plot. Total cfDNA is isolated from a patient’s plasma
and sequenced. From sequencing results, human cfDNA are removed after mapping and only unmapped reads are further processed. From
these unmapped reads, microbial species are classified and reads are normalized, counted, and sorted by their abundance. For each species
obtained from a patient, results are compared with likewise processed samples of uninfected controls, exemplified for microbial species X, which
is found in the patient’s sample as well as in most control samples and, therefore, represents a contaminant. However, species Y is found in high
abundance only in the patient’s sample and in none of the controls and, therefore, receives a high significance and consequently a high SIQ
score, indicated by the radius of its data point in the SIQ plot. b Distribution of normalized counts for each species found in the plasma sample
of patient S9 at the onset of sepsis (T0). Only the most abundant species, Enterobacter cloacae, was labeled. c Distribution of the normalized
counts for E. cloacae for all samples analyzed. Red, septic patients; blue, controls (elective surgery and healthy volunteers). Only sample S9 with
the most abundant E. cloacae reads was labeled. d Distribution of the normalized counts of Propionibacterium acnes for all samples. Red, septic
patients; blue, controls (elective surgery and healthy volunteers). e SIQ plot integrating abundance and significance of all species for patient S9 at
the onset of sepsis (T0). Coordinates of the data points (species) are the relative abundance (log2) on the x-axis and the significance expressed as
1 − p value on the y-axis. The dashed line marks a p value of 0.05. Data points with log2 > 0 and p value <0.05 are labeled. The SIQ score of a
species in the respective sample is integrated as the radius of the data point
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to remove a tumor of his stomach (Fig. 3a). On study
inclusion, blood culture and subsequent samples from
different sites were positive for Staphylococcus aureus.
In addition to S. aureus, significant viral burden (herpes
simplex virus 1 (HSV1); 9.87 × 106 copies/ml) and low
fungal burden (Candida albicans) were also detected in
other specimens by quantitative PCR (qPCR) or cultiva-
tion, respectively. Sequencing of plasma samples con-
firmed S. aureus as the predominant organism in the
patient’s blood at all observed time points with SIQ
scores of 125.24, 720.41, 12.86, 2, and 0.03. Interestingly,
the highest SIQ score for S. aureus was observed one
day following inclusion and strongly declined afterwards.
On day 7 the highest SIQ score was obtained for HSV1
(43.07), which was also detected by qPCR on day 14 in
tracheal secretions (8.5 × 105 copies/ml) but otherwise in
no other sample (qPCR or NGS). Patient S60 (Fig. 3b)
suffered from recurring episodes of bowel leakage accom-
panied by several septic hits and underwent repetitive
reconstructive abdominal surgery. Remarkably, during the
course of sepsis, no blood culture was positive for this
patient, with the exception of a single bottle positive for
Staphylococcus epidermidis one day before study inclu-
sion. However, wound swabs and intraabdominal lavage
were positive for Escherichia coli and Enterococcus
faecium. Tracheal secretions furthermore tested positive
for HSV1 and/or C. albicans. During the course of
infection, the patient developed a ventilator-associated
pneumonia which was due to E. coli, Stenotrophomonas
maltophilia, and Klebsiella pneumoniae. In contrast to
standard blood culture, SIQ score analyses of this patient’s
plasma were in good agreement with non-blood culture
clinical microbiology results over the complete time
course. Samples collected at the early septic phase (days 0,
1, 4, 7, 14, and 21) confirmed the clinical representation of
a polymicrobial abdominal infection due to E. coli, E.
faecium, and Bacteroides fragilis. Furthermore, results
from qPCR of HSV1 from tracheal secretions could be
confirmed by NGS (day 7). The progression of the patient
towards ventilator-associated pneumonia at the end of our
study period was also confirmed by SIQ scores of 1341.37
for K. pneumonia and 68.58 for B. fragilis in plasma
obtained on day 28. For additional patients NGS results
from plasma samples matched data from other specimens,
such as tracheal secretion, swabs, or catheter cultivation
(Additional files 10, 11, and 12: Figures S5–S7).
Identification of resistance genes
Resistance to antibiotics is mediated by the expression of
resistance genes, including mecA or vanA/B mediating
resistance to methicillin or vancomycin in Gram-positive
cocci, for example. We analyzed one plasma sample
from a 59-year-old woman that suffered from sepsis fol-
lowing liver transplantation. Sequencing the corresponding
plasma cfDNA at high depth (Additional file 13: Table S4)
showed even coverage of the E. faecium genome (Fig. 4a;
Additional file 14: Figure S9) and revealed unambiguous
hits for resistance genes in the CARD database, including
vanB, vanSB, tet1, and sat4 (Fig. 4b). Remarkably, our find-
ings match with microbiological data showing that the in-
fectious organism was E. faecium exhibiting vancomycin
and tetracycline resistance (VRE), among others. Thus, as-
suming a sufficient sequence coverage, identification of
genes conferring resistance using an unbiased high-
throughput sequencing approach seems to be possible in
principle.
Discussion
In recent years, several reports have been published on
the use of metagenomics for the identification of viruses
or microbes in patient samples. Most of these reports
describe the identification of different viruses, including
influenza A, norovirus, Ebola, arenaviruses, or emerging
viruses from various specimens like nasopharyngeal
swabs, serum, or solid tissue [23–29]. In addition, meta-
genomics, amongst other methods, has also been applied
for identification of bacteria from urine, vaginal swabs,
or sputum [30–33]. However, to the best of our know-
ledge, we report here the first proof-of-concept for
quantitative NGS-based diagnosis of septicemia using
plasma samples from septic patients and uninfected con-
trols based on free circulating DNA. Several attempts
have been made to use cfDNA quantification as a diagnos-
tic and prognostic marker for sepsis outcome [34–36].
However, elevated cfDNA levels resulting from apoptotic
or necrotic processes have also been described in other
physiologic or pathologic conditions, including pregnancy,
exercise, inflammatory diseases, trauma due to stroke,
cancer, and surgery. Consequently, it is controversial
whether elevated levels of circulating cfDNA are of diag-
nostic and prognostic value per se [36, 37]. Five out of
seven septic patients (S9, S10, S19, S23, S60) underwent
major abdominal surgery within 2 days of sepsis onset,
which likely contributed to elevated cfDNA concentra-
tions. However, septic patients showed a significantly
higher share of cfDNA that could be assigned to microbial
origin, suggesting a direct release of DNA from bacteria
or co-release from phagocytic cells. This cfDNA could ori-
ginate from both live and dead pathogens. However, as
cfDNA is subject to considerable turnover, with a half-life
in the range of minutes [38, 39], and obtained SIQ scores
are very dynamic during the time course of infection, this
suggests that cfDNA levels from microbial origin seem to
precisely reflect the dynamics of infection, irrespective of
whether cfDNA is released by dead or living cells. Due to
the very short half-life of cfDNA, we therefore would also
not expect to face a significant false positive rate. How-
ever, as our study only comprises a limited number of
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cases, further research and more comprehensive cohorts
are needed to elucidate the source and mechanism of
cfDNA release and its impact on false positive rates.
In patients suffering from severe sepsis or septic
shock, positive blood cultures are obtained in only a
fraction of cases despite a proven underlying rate of bac-
terial infection of 33 % [40–42]. This is partially attribut-
able to technical shortfalls in blood culture acquisition
but is also due to fastidious organisms or very low rates
of viable microorganisms in the blood stream [43]. A
molecular approach with higher sensitivity for sepsis
might, therefore, overcome the aforementioned limitations
of classic microbiological diagnostics. However, state of
the art molecular approaches based on PCR amplification
of target sequences suffer from limited power to discrimin-
ate between contaminations, colonization, and infections,
Fig. 4 Genome coverage and resistance profile of a patient infected with vancomycin-resistant E. faecium (VRE). a Mean genome coverage of
approximately 0.3 of the E. faecium genome (2.8 Mb). b Table with hits to the CARD database. The CARD/GenBank accession number is listed as
well as the alias gene name, gene coverage calculated from read length ratio to gene length, number of reads mapped to this gene, and the
respective organism to which the sequence is assigned
(See figure on previous page.)
Fig. 3 Time course SIQ analyses compared with conventional clinical microbiology data for two patients. a Time course of patient S10. A 68-year-
old male patient presented with a tumor of his stomach with the need for a gastrectomy. Following the surgical procedure the patient suffered
from septic shock due to severe pneumonia without any evidence of an anastomosis insufficiency. Staphylococcus aureus was shown to be the
dominant organism in different secretions (e.g., tracheal secretion, abdominal wound swab, blood culture, etc.). In addition, pneumonia was
shown to be accompanied (respectively boosted) by reactivation of herpes simplex virus type 1 (HSV1) in tracheal secretions. Following a
prolonged weaning phase, the patient was then able to be discharged to the normal ward 6 weeks after the onset of septic shock. In this figure,
the antibiotic treatment regime, SIQ scores for species identified via NGS/SEPseq, and cfDNA concentrations of the respective plasma samples are
plotted for the trial period of 28 days. Pertinent (clinical microbiology) laboratory results are marked using arrows to indicate the day the clinical
specimen was obtained. Abbreviations: BC blood culture, CVC central venous catheter, TS tracheal secretion, HSV herpes simplex virus, CIP ciproflocaxine,
MTZ metronidazole, MEM meropenem, VAN vancomycin, CFG caspofungin, FLX flucloxacillin, FLC fluconazole, ACV aciclovir, AFG anidulafungin, TGC
tigecycline. Anti-infectives are displayed as antibacterial antibiotics, antimycotics, and antivirals in light grey, black, and dark grey, respectively. The
relative amount of bacteria found by conventional clinical microbiology is indicated with plenty (p), medium (m), or scarce (s). (For a detailed list of the
anti-infective abbreviations, see Table S5.) b Time course of patient S60. Following a complicated course of perforated sigmoid diverticulitis, a 70-year-old
female patient presented for reconstruction of bowel continuity. In the postoperative phase the patient developed septic shock due to bowel leakage
with the need for surgical revision. Abdominal wound swabs were shown to be positive for Escherichia coli and Enterococcus faecium. One day later the
patient suffered from a second septic hit due to perforation of the colon with the need for surgical colectomy and construction of a stump by Hartmann.
Afterwards the patient suffered from another septic hit due to an insufficiency of the stump by Hartmann. Accordingly, one further explorative
laparotomy was performed and an intensive abdominal lavage was initiated. In the further course of the septic disease the patient developed a
fourth septic hit due to ventilator-associated pneumonia triggered by E. coli, Stenotrophomonas maltophilia, and Klebsiella pneumoniae. Following a
prolonged weaning phase the patient was then able to be transferred to the intermediate care ward after 3 months of ICU treatment. Ultimately, the
patient could be discharged from hospital another 2 weeks later. Pertinent (clinical microbiology) laboratory results are marked using arrows to indicate
the day the clinical specimen was obtained. Abbreviations: BC blood culture, CVC central venous catheter, TS tracheal secretion, BAL bronchoalveolar
lavage, HSV1 herpes simplex virus 1, IPM imipenem, LZD linezolid, CFG caspofungin, ACV aciclovir, TZP piperacillin-tazobactam, CTX cotrimoxazol, CAZ
ceftazidime. Antibacterial antibiotics are colored in light grey. The relative amount of bacteria found by conventional clinical microbiology is indicated
with plenty (p), medium (m), or scarce (s). (For a detailed list of the anti-infective abbreviations, see Additional file 9: Table S5)
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often revealing ambiguous or invalid results. In this con-
text, NGS-based diagnostic testing might offer several ad-
vantages over PCR assays: (i) NGS is an open platform,
providing the opportunity to detect bacterial, fungal, and
viral pathogens in a single assay; (ii) NGS is quantitative
through counting of sequence reads and calculation of
statistical significance; (iii) NGS is unbiased and untar-
geted so benefits from any DNA sequence information
within patient specimens, potentially delivering higher sen-
sitivity and specificity. However, although NGS is becom-
ing increasingly important in clinical microbiology (e.g.,
for strain typing), only sporadic reports of NGS-analyzed
clinical specimens have been published to date, including
one actionable single-case report of NGS-based diagnosis
of Leptospira from cerebrospinal fluid [44–49]. Another
recent paper, by De Vlaminck and coworkers [50], reports
the identification of predominantly viral pathogens in
cfDNA from patients after lung transplantation. Neverthe-
less, we currently lack NGS-based diagnostic approaches
that, by combining quantitative values with statistical sig-
nificance, provide a measure for relevance. Especially in
specimens like plasma, where only the lowest amounts of
microbial DNA can be expected, the specificity is chal-
lenged by the detection of microbial contaminants from la-
boratory reagents, workflows, or specimen sampling [18,
51]. We therefore developed a SIQ score to discriminate
signal reads from noise caused by contaminant or com-
mensal species. Since the incidence of viral and fungal in-
fections in sepsis is less frequent, the SIQ scores for fungi
and viruses will generally be higher than those for bacteria
(as seen in patient S23; Additional file 11: Figure S6) as
they are also less often detected in control samples. Conse-
quently, the robustness of the SIQ score will be increased
by using the most complete database of relevant genomes
and a control group large enough to capture even small
variances in the microbiome of healthy individuals.
Using our current workflow, a good correlation of NGS
results with blood culture and other patient specimens was
observed for all patients except patient S60. Moreover, this
agreement was observed not only for bacteria but also for
viruses and fungi. For patient S60 we found E. coli and E.
faecium in plasma, which is in good agreement with
wound swab findings but in contrast to blood culture,
where S. epidermidis was identified one day before. Clinical
records suggest that this patient suffered from gut compli-
cations, indicating that the NGS-based approach might be
more sensitive and specific than blood culture, which has
to be systematically evaluated by further studies.
Importantly, we could also demonstrate the potential
of quantitative NGS-based diagnosis to identify genes
conferring antibiotic resistance in plasma cfDNA. We
unambiguously identified from a septic patient that
underwent liver transplantation a number of reads that
match with 100 % identity to vanB and vanSB, known to
confer resistance to vancomycin. Indeed, we could iden-
tify VRE as the infecting strain as confirmed by micro-
biological testing. Meanwhile, we were also able to
detect mecA from methicillin-resistant S. aureus in other
patient plasma samples (data not shown), indicating that
the identification of major resistance genes is feasible
with our approach. However, the applicability of the
CARD antibiotic resistance database for diagnostic pur-
poses is currently limited to genes which, per se, confer
resistance to antibiotics, whereas the heterogeneity of re-
sistance mechanisms also comprises point mutations,
gene expression changes, and posttranslational modifica-
tions, for example. Consequently, using the current
setup of the database and workflows, it is possible to
identify resistance mechanisms based on acquisition of
specific resistance genes like mecA, vanA/B, KPC, etc.
but not necessarily to detect all resistance mechanisms
comprehensively. Furthermore, it should be noted that
mapping of reads to resistance-related genes relies on
high read coverage for the respective species. For routine
detection of resistance genes, enrichment strategies and
complementation with expression data might be helpful
in elucidating additional resistance mechanisms.
Finally, using our workflow to quantitatively identify
microbial and viral nucleic acids in patient plasma
(Additional file 15: Figure S8), the current total turn-
around time starting from plasma adds up to approxi-
mately 31 h, where the most time-consuming step is
sequencing, which was accomplished in rapid run mode
on a HiSeq2500 within 16 h. This is competitive with
standard blood culture with a time to positivity of 24–
120 h, where automated blood culture systems are rou-
tinely incubated for 5 days [43]. However, recent devel-
opments in sequencing technologies (i.e., Oxford
Nanopore’s MinION device) indicate that it will be pos-
sible to sequence even larger amounts of DNA in
shorter times in a bedside setup. Using this technology it
has already been reported that strain identification of
clinically relevant strains and the corresponding resist-
ance profiles is possible in approximately 2 h [52]. Fur-
thermore, the identification of resistance genes has been
shown to be manageable in 2 to 12 h, which makes a
“same day” diagnosis possible [52]. Nanopore sequencing
would, therefore, allow a diagnostic decision within 3–
4 h after initial diagnosis of sepsis using our workflow,
providing a reasonable timeframe for effective thera-
peutic intervention. It should also be mentioned that
current sequencing costs are of considerable importance
for diagnostics. Although costs per base are constantly
dropping, diagnostic approaches based on NGS are still
comparatively expensive. Therefore, we expect that such
a diagnostic workflow will be in a cost range similar to
that of noninvasive prenatal testing (NIPT) when it was
introduced several years before. This might limit a
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corresponding approach for diagnosis in critically ill
patients in the beginning, for whom overall costs per
patient and day are relatively high. But as seen for
NIPT, costs per assay might significantly drop in short
order following a broader application of NGS in clinics,
thus making such an approach conceivable also from a
financial point of view.
Conclusions
This work shows for the first time that identification of
viruses, bacteria, and fungi from cfDNA in plasma of
septic patients not only is technically feasible but also
provides a basis to differentiate the relevant infecting
organisms by establishing a quantitative score. These
characteristics go beyond state-of-the-art molecular ap-
proaches for the diagnosis of infecting organisms in sep-
tic specimens, which are not open but instead based on
PCR amplification of defined targets and are, in most
cases, just qualitative in nature. Therefore, this approach
allows for an unbiased analysis of bloodstream infec-
tions, which might be especially useful for the diagnosis
of cases where classic microbiological or molecular diag-
nostic approaches fail. However, although we think that
our approach might be more sensitive and specific than
state-of-the-art technologies, additional clinical trials will
be needed to exactly define the sensitivity and specificity
as well as the positive and negative predictive value as
this case study was limited by the low number of
patients.
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in the kraken database to identify microbial reads in non-human reads.
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Additional file 2: Figure S1. Bioanalyzer profiles of cfDNA isolated
from septic patients, non-infected (post-)surgery controls, and healthy
volunteers. a Gel-like visualization of the cfDNA profiles run on the Agilent
Bioanalyzer with a High Sensitivity DNA chip. b Corresponding
electropherograms, where the two outermost peaks are internal size
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Additional file 3: Table S6. Total read counts per sample and species.
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Additional file 4: Figure S2. Distribution of species-specific normalized
read counts in septic patients and controls for major pathogens in the
sepsis setting. Red: septic patients, blue: controls (elective surgery
(timepoint T0) and healthy volunteers). (PDF 19 kb)
Additional file 5: Figure S3. Distribution of species-specific normalized
read counts in septic patients and controls for potential contaminant
species. Red, septic patients; blue, controls (elective surgery (timepoint T0)
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Additional file 8: Figure S4. SIQ plot for post-surgery patients P1 T1
and P2 T1. (PDF 72 kb)
Additional file 9: Table S5. Anti-infective abbreviations. (XLSX 9 kb)
Additional file 10: Figure S5. Time course of patient S9. An 82-year-
old male patient presented with a tumor of his bile duct with the need
for an enlarged right-sided hemihepatectomy. Following the surgical
procedure, the patient suffered from septic shock due to Ogilvie syndrome
and a right-sided hemicolectomie had to be performed. Septic shock
was paralleled by repetitive positive blood cultures with Enterobacter
cloacae, which was shown to be the cause of ventilator-associated
pneumonia 1 week after sepsis onset. Following antibiotic treatment,
two different biotypes of E. cloacae could be observed, both fulfilling
the criteria of being multidrug resistant. The patient died 9 weeks after
the onset of septic shock. In this figure, the antibiotic treatment regime,
SIQ scores for species identified via NGS, and cfDNA concentrations of the
respective plasma samples are plotted over the timeline of the trial period
for patient S9. Pertinent clinical microbiology laboratory results are marked
using arrows to indicate the day the clinical specimen was obtained.
Abbreviations: BC blood culture, CVC central venous catheter, TS tracheal
secretion, NL non-lysing, CIP ciproflocaxine, MTZ metronidazole, IPM
imipenem, LZD linezolid, FLC fluconazole, VAN vancomycin. Anti-infectives
are displayed as antibacterial antibiotics, antimycotics, and antivirals in light
grey, black, and dark grey, respectively. The relative amount of bacteria found
by conventional clinical microbiology is indicated with plenty (p), medium
(m), or scarce (s). (For a detailed list of the anti-infective abbreviations,
see Additional file 9: Table S5.) (PDF 16 kb)
Additional file 11: Figure S6. Time course of patient S11. A 62-year-old
male patient presented with a multilocular hepatocellular carcinoma with
the need for a left-sided hemihepatectomy. Following the surgical procedure
the patient suffered from septic shock due to severe pneumonia with
Klebsiella pneumoniae as the dominant organism in blood cultures as well as
tracheal secretions. Empiric antibiotic therapy was performed with
imipenem, which was then switched to moxifloxacin based on the
susceptibility findings. In the further course of the disease, K. pneumoniae
was shown to be multidrug resistant. Although antibiotic therapy was
adapted according to the findings of susceptibility testing, the pulmonary
septic focus could not be removed sufficiently. In the end, the patient died
from ongoing septic shock due to pneumonia with K. pneumonia 2 months
after study inclusion. In addition, septic disease was shown to be accompanied
by a reactivation of herpes simplex virus type 1 (HSV1) as well as
cytomegalovirus (CMV) in different secretions as assessed by a PCR-based
diagnostic procedure. These findings were in good agreement with next
generation sequencing (NGS) of plasma. In this figure, the antibiotic
treatment regime, SIQ scores for species identified via NGS, and cfDNA
concentrations of the respective plasma samples are plotted over the
timeline of the trial period for patient S11. Pertinent (clinical microbiology)
laboratory results are marked using arrows to indicate the day the clinical
specimen was obtained. Abbreviations: BC blood culture, CVC central venous
catheter, TS tracheal secretion, GNST Gram-negative staphylococci, HSV1
herpes simplex virus 1, IPM imipenem, VAN vancomycin, MXF moxiflocaxin,
CIP ciprofloxacin, TGC tigecycline, CAZ ceftazidime. Antibacterial antibiotics
are displayed in light grey. The relative amount of bacteria found by
conventional clinical microbiology is indicated with plenty (p),
medium (m), or scarce (s). (For a detailed list of the anti-infective
abbreviations, see Additional file 9: Table S5) (PDF 16 kb)
Additional file 12: Figure S7. Time course of patient S23. A 77-year-old
male patient presented with septic shock due to an acute abdominal
infection. An ischemic colitis with a perforation of the sigma and severe
peritonitis was identified to be the septic focus, so the patient underwent
surgical colectomy. Abdominal wound swabs as well as the corresponding
blood cultures were shown to be positive for Enterococcus faecium 2 days
before inclusion in the study cohort. Empiric antibiotic therapy with
imipenem and linezolid was therefore proven to be appropriate. In
addition, this patient also revealed a reactivation of herpes simplex virus
type 1 (HSV1) in tracheal secretions. These PCR-based findings could also
be confirmed by next generation sequencing (NGS) of plasma. The
antibiotic treatment regime, SIQ scores for species identified via NGS,
and cfDNA concentrations of the respective plasma samples are plotted
over the timeline of the trial period for patient S23. Pertinent (clinical
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microbiology) laboratory results are marked using arrows to indicate the
day the clinical specimen was obtained. Abbreviations: BC blood culture,
TS tracheal secretion, CoNST coagulase negative staphylococci, IMP
imipeneme, LZD linezolid, TZP tazobactam, CLI clindamycin, FLC fluconazole.
Anti-infectives are colored as antibacterial antibiotics and antimycotics in
light grey and black, respectively. The relative amount of bacteria found by
conventional clinical microbiology is indicated with plenty (p), medium (m),
or scarce (s). (For a detailed list of the anti-infective abbreviations,
see Additional file 9: Table S5.) (PDF 15 kb)
Additional file 13: Table S4. Sequencing characteristics of the resistance-
characterized patient sample. (XLSX 8 kb)
Additional file 14: Figure S9. Mapping of Enterococcus faecium
identified reads on the genome of Enterococcus faecium DO (NC_017960.1)
using different minimum identity values while mapping. a Minimum
identity of 65 %; b minimum identity of 70 %; c minimum identity of 85 %;
d minimum identity of 90 %; e minimum identity of 95 %; f minimum
identity of 100 %. (PDF 382 kb)
Additional file 15: Figure S8. Workflow and time distribution of
NGS-based pathogen identification and blood culture. Flow chart and bar
chart of the individual steps and the time required for the NGS-based
identification of bacteremia-causing species and conventional blood
culture. As time to positivity varies substantially, a time frame of 24 to
120 h is given for blood culture. (PDF 42 kb)
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cfDNA, cell-free DNA; HSV, herpes simplex virus; NGS, next generation
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